

Communications to the Editor

A Novel, Potent, and Selective 5-HT₇ Antagonist: (*R*)-3-(2-(2-(4-Methylpiperidin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970)

Peter J. Lovell,^{*,†} Steven M. Bromidge,[†] Steven Dabbs,[†] D. Malcolm Duckworth,[†] Ian T. Forbes,[†] Andrew J. Jennings,[†] Frank D. King,[†] Derek N. Middlemiss,[‡] Shirley K. Rahman,[†] Damian V. Saunders,[†] Lissa L. Collin,[‡] Jim J. Hagan,[‡] Graham J. Riley,[‡] and David R. Thomas[‡]

SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex CM19 5AW, U.K.

Received August 27, 1999

Introduction. The human 5-HT₇ receptor is a recently discovered member of the seven-transmembrane G-protein-coupled receptor superfamily.² The most abundant isoform 5-HT_{7(a)} consists of a 445-amino acid polypeptide with a relatively short third intracellular loop and a long carboxy terminus. 5-HT₇ receptors have been cloned from rat,^{3–5} mouse,⁶ guinea pig,⁷ and human⁸ cDNA. Sequence alignments show a high degree of interspecies homology (95%) but a low overall homology (<40%) with other 5-HT receptors. The 5-HT₇ receptor is positively coupled to adenylyl cyclase through G_s when expressed in cell lines.^{3–5,8} The greatest abundance of 5-HT₇ receptor mRNA is found in the brain where it is localized in the thalamus, hypothalamus, and various limbic and cortical regions in rats,^{3,5} humans,⁸ and guinea pigs.⁹ Autoradiography studies using [³H]5-CT confirm that the distribution of 5-HT₇ binding sites in rat and guinea pig brain matches, to a large extent, the mRNA distribution.^{9–11} Although the biological functions of the 5-HT₇ receptor are poorly understood, receptor localization, combined with some preliminary pharmacological studies in rat, suggests that 5-HT₇ receptors play a role in mediating 5-HT-induced phase shifts of neuronal activity in the suprachiasmatic nucleus of the hypothalamus.⁴ These data suggest that 5-HT₇ receptors might be linked to the control of circadian rhythms.¹²

Further pharmacological evaluation has been hampered by the lack of selective ligands. However, we recently reported the synthesis and biological activity of the sulfonamide **1** (Chart 1), the first potent 5-HT₇ receptor antagonist with 100-fold selectivity over a wide range of receptors.¹ More recently a series of tetrahydrobenzindoles have been reported as potent 5-HT₇ receptor antagonists (e.g. **3**, p*K_i* 8.7) although selectivity over 5-HT₂ receptors was only 50-fold.¹³ In this com-






Figure 1. Ramachandran plot. Rotation about the N(Me)–C(Me) bond (T2) reveals an energy minima when the two methyl groups are orientated gauche (60°).

Chart 1. 5-HT₇ Antagonists




munication we report the further optimization of **1** by conformational restraint of the side chain which has led to more potent and selective compounds exemplified by **15**.

Results and Discussion. A key finding from our earlier SAR study was the importance of the chiral center in the flexible side chain in compounds such as **1** and **2**. Conformational analysis of this side chain using MACROMODEL¹⁴ revealed that all bonds are relatively free to rotate apart from the S–N and N(Me)–C(Me) bonds. A Ramachandran plot (Figure 1) showing rotation around these two bonds in **2** was constructed and reveals an energy minimum when the two methyl

* To whom correspondence should be addressed. E-mail: Peter_J.Lovell@sbphrd.com.

[†] Department of Discovery Chemistry.

[‡] Department of Neuroscience Research.


Scheme 1^a

^a Reagents: (a) naphthalene-1-sulfonyl chloride, diisopropylethylamine, CH₂Cl₂ (53%); (b) 4-methylpiperidine, NaI, K₂CO₃, CH₃CN (88%).

groups are orientated gauche (T2 = 60°) with respect to each other, which may represent the binding conformation. This suggested the synthesis of analogues in which both methyl groups have been tied together into a ring. Therefore we targeted analogues incorporating both 2-pyrrolidinyethyl and 2-piperidinyethyl side chains. Docking of **5** into our 5-HT₇ receptor homology model, constructed on the basis of recent electron microscopy studies by Baldwin,¹⁵ predicted that (*R*)-**5** would have the lower binding energy.

Synthesis of the six-membered constrained side chain (Scheme 1) started with reaction of piperidine-2-ethanol with 2 equiv of naphthalene-1-sulfonyl chloride to give **4**. Displacement of the chloride with 4-methylpiperidine using sodium iodide to catalyze the reaction gave the racemic sulfonamide (*RS*)-**5**, in good overall yield. Preparation of the individual enantiomers (*R*)-**5** and (*S*)-**5** was achieved using the same route, starting with (*R*)- and (*S*)-piperidine-2-ethanol,¹⁶ respectively.

The starting points for the syntheses of the chiral five-membered analogues were (*R*)- and (*S*)-pyrrolidinol (Scheme 2). BOC protection of each pyrrolidinol allowed transformation of the primary alcohols into the corresponding mesylates **7**. Displacement with sodium cyanide in DMF gave the nitriles **8**, which were transformed into the protected side chains **9** by hydrogenation over Pt catalyst in the presence of 4-methylpiperidine. Removal of the BOC protection using TFA and reaction with naphthalene-1-sulfonyl chloride gave the target sulfonamides **10** in good overall yield.

Scheme 2^a

^a Reagents: (a) BOC anhydride, THF/H₂O, K₂CO₃ (84%); (b) methanesulfonyl chloride, Et₃N, CH₂Cl₂ (100%); (c) NaCN, DMF (78%); (d) 4-methylpiperidine, H₂, PtO₂ (47%); (e) trifluoroacetic acid, CH₂Cl₂ (100%); (f) naphthalene-1-sulfonyl chloride, diisopropylethylamine, CH₂Cl₂ (60%).

The receptor binding affinity of the racemate (*RS*)-**5** for the 5-HT_{7(a)} receptor (Table 1) was comparable to that of the unconstrained analogue **2**. (*R*)-**5** has a p*K*_i of 7.8 for the 5-HT_{7(a)} receptor which is 25-fold greater than that of (*S*)-**5** demonstrating that the *R* enantiomer has greater activity at the 5-HT₇ receptor, as predicted by modeling. This was confirmed in the more constrained five-membered series where similar differences were seen between the *R* and *S* enantiomers. (*R*)-**10** demonstrated a slightly higher 5-HT_{7(a)} receptor affinity (p*K*_i 8.0) compared to (*R*)-**5**, indicating that the pyrrolidine ring constrains the side chain in a more optimum conformation for 5-HT₇ binding.

Using the optimized (*R*)-pyrrolidinyethyl side chain, further investigations into the effect of aromatic substitution on 5-HT₇ receptor affinity and selectivity were carried out. In general the SAR for the constrained five-membered side chain paralleled that already seen for the unconstrained side chain.¹ Lipophilic substituents in both the 3- and 4-positions of the aromatic ring are well-tolerated, with **11–13** all giving highly potent and selective compounds (Table 2). Surprisingly, introduction of a polar 3-hydroxy group to afford **15** resulted in a compound with the highest 5-HT_{7(a)} receptor affinity (p*K*_i 8.9). Cross-screening data showed that **15** also has an excellent selectivity profile (>250-fold) over 13 other receptors apart from the 5-HT_{5A} receptor (50-fold).


Table 1. Receptor Binding Profiles in Radioligand Binding Assay^{a,b}

	5-HT _{1A}	5-HT _{1B}	5-HT _{1D}	5-HT _{1E}	5-HT _{1F}	5-HT _{2A}	5-HT _{2B}	5-HT _{2C}	5-HT ₄	5-HT ₆	5-HT _{7(a)}	adren α _{1b}	dopam D ₂	dopam D ₃
(<i>RS</i>)-5	—	<5	5.7	<5	<5	<5.5	5.4	<5	—	—	7.4	—	—	—
(<i>R</i>)-5	5.8	<5.5	6.3	<5	<5	<5.6	5.4	<5	—	—	7.8	<6	6.4	6
(<i>S</i>)-5	—	—	—	—	—	—	—	—	—	—	6.4	—	—	—
(<i>R</i>)-10	6.0	5.4	6.2	<5	<5	5.8	5.7	6.0	—	—	8.0	5.6	6.2	5.9
(<i>S</i>)-10	—	—	—	—	—	—	—	—	—	—	6.4	—	—	—

^a All values represent the mean of at least two determinations carried out using cell lines stably expressing the cloned receptors. Each determination lies within 0.2 log unit of the mean. ^b Receptors and radioligands used in binding assays: 5-HT_{1A} (human cloned receptors in HEK 293 cells; [³H]8-OH-DPAT); 5-HT_{1B} (human cloned receptors in CHO cells; [³H]5-HT); 5-HT_{1D} (human cloned receptors in CHO cells; [³H]5-HT); 5-HT_{1E} (human cloned receptors in CHO cells; [³H]5-HT); 5-HT_{1F} (human cloned receptors in CHO cells; [³H]5-HT); 5-HT_{2A} (human cloned receptors in HEK 293 cells; [³H]ketanserin); 5-HT_{2B} (human cloned receptors in HEK 293 cells; [³H]5-HT); 5-HT_{2C} (human cloned receptors in HEK 293 cells; [³H]mesulergine); 5-HT₆ (human cloned receptors in HeLa cells; [³H]LSD); 5-HT_{5A} (human cloned receptors in HEK 293 cells; [³H]5-CT); 5-HT_{7(a)} (human cloned receptors in HEK 293 cells; [³H]5-CT); D₂ (human cloned receptors in CHO cells; [¹²⁵I]iodosulpiride); D₃ (human cloned receptors in CHO cells; [¹²⁵I]iodosulpiride).

Table 2. Effect of Aromatic Substitution on 5-HT₇ Affinity and Selectivity^{a,b}

	R	5-HT _{1A}	5-HT _{1B}	5-HT _{1D}	5-HT _{1E}	5-HT _{1F}	5-HT _{2A}	5-HT _{2B}	5-HT _{2C}	5-HT ₄	5-HT _{5A}	5-HT ₆	5-HT _{7(a)}	adren α _{1b}	dopam D ₂	dopam D ₃
11	3,4-dichloro	6.5	5.8	6.2	5.6	<5.5	<6	<6	<6	<5.5	—	—	8.4	5.7	6.0	6.0
12	3-bromo	6.4	6.0	6.3	<5.6	<5.3	<5.3	<5.8	<5.3	<5.2	—	5.5	8.7	—	6.1	6.2
13	3-methyl	6.0	5.8	5.5	<5	<5	<5.3	<5.6	<5.3	<5	—	—	8.5	<5.5	5.8	5.9
14	3-methoxy	—	—	—	—	—	—	—	—	—	—	<5	8.0	—	—	—
15	3-hydroxy	<5	6.0	5.8	<5.2	<5.5	<5	5	<5	5.9	7.2	5.2	8.9	<5	6.5	5.6

^{a,b} See Table 1 for details.**Figure 2.** Functional model of 5-HT₇ receptor activation. Stimulation of adenylyl cyclase activity in human 5-HT₇/HEK293 membranes by 5-CT alone (control) and in the presence of SB-269970 (0.3 μM). Data points represent the mean ± SEM of at least three separate experiments each performed using duplicate determinations.

Furthermore, in a commercial screening package (Cerep) **15** was found to be over 100-fold selective against a total of 50 receptors, enzymes, or ion channels. Compound **15** shows a substantial increase in 5-HT₇ receptor affinity when compared to the methoxy derivative **14**, suggesting a favorable interaction between the hydroxyl group and the receptor. We were able to rationalize this finding by docking **15** into our 5-HT₇ homology model which revealed an additional hydrogen-bonding interaction site.

Compound **15** was evaluated in a functional model of 5-HT₇ receptor activation by examination of adenylyl cyclase activity in HEK 293 cells stably expressing the human 5-HT_{7(a)} receptor. The nonselective 5-HT₇ receptor agonist 5-CT stimulated basal adenylyl cyclase activity with a pEC₅₀ of 7.5 ± 0.1 (*n* = 3) (Figure 2). In the presence of compound **15**, the 5-CT concentration–response curve had the same maximal response but was shifted rightward in a parallel manner indicating competitive, surmountable antagonism of the response. The calculated pK_B of 8.3 ± 0.1 (*n* = 3) is in reasonable agreement with the receptor binding affinity. In addition, **15** produced a small apparent reduction in basal adenylyl cyclase activity in the absence of added 5-CT. This is consistent with inverse agonism which has previously been reported for **1** (SB-258719) and a number of nonselective 5-HT receptor antagonists.¹⁷

In conclusion, conformational analysis of the flexible side chain in **1** indicated a low-energy, potential binding

conformation in which the two methyl groups adopt a gauche orientation. The design and preparation of analogues that mimic this conformation led to the discovery of **15**, a highly potent and selective 5-HT₇ receptor antagonist. These compounds are currently being used to evaluate the therapeutic potential of 5-HT₇ ligands.

Supporting Information Available: Experimental details for the synthesis of compounds **4**–**15**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- Forbes, I. T.; Dabbs, S.; Duckworth, D. M.; Jennings, A. J.; King, F. D.; Lovell, P. J.; Collin, L.; Hagan, J. J.; Middlemiss, D. N.; Riley, G. J.; Thomas, D. R.; Upton, N. (*R*)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide: The First Selective 5-HT₇ Receptor Antagonist. *J. Med. Chem.* **1998**, *41*, 655–657.
- Eglen, R. M.; Jasper, J. R.; Chang, D. J.; Martin, G. R. The 5-HT₇ receptor: orphan found. *Trends Pharmacol. Sci.* **1997**, *18*, 104–107.
- Shen, Y.; Monsma, F. J.; Metcalf, M. A.; Jose, P. A.; Hamblin, M. W.; Sibley, D. R. Molecular Cloning and Expression of a 5-HT₇ Serotonin Receptor Subtype. *J. Biol. Chem.* **1993**, *268*, 18200–18204.
- Lovenberg, T. W.; Baron, B. M.; Lecea, L. de; Miller, J. O.; Prosser, R. A.; Rea, M. A.; Foye, P. E.; Rucke, M.; Slone, A. L.; Siegel, B. W.; Danielson, P. E.; Sutcliffe, J. G.; Erlander, M. G. A Novel Adenylyl Cyclase-Activating Serotonin Receptor (5-HT₇) Implicated in the Regulation of Mammalian Circadian Rhythms. *Neuron* **1993**, *11*, 449–458.
- Ruat, M.; Traiffort, E.; Leurs, R.; Tardivel-Lacombe, J.; Diaz, J.; Arrang, J.-M.; Schwartz, J.-C. Molecular Cloning, Characterisation and Localisation of a High Affinity Serotonin Receptor (5-HT₇) Activating cAMP Formation. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 8547–8551.
- Plassat, J.-L.; Amlaiky, N.; Hen, R. Molecular Cloning of a Mammalian Serotonin Receptor that Activates Adenylate Cyclase. *Mol. Pharmacol.* **1993**, *44*, 229–236.
- Tsou, A.-p.; Kosaka, A.; Bach, C.; Zuppan, P.; Yee, C.; Tom, L.; Alvarez, R.; Ramsey, S.; Bonhaus, D. W.; Stefanich, E.; Jakeman, L.; Eglen, R. M.; Chan, H. W. Cloning and Expression of a 5-HT₇ Receptor Positively Coupled to Adenylyl Cyclase. *J. Neurochem.* **1994**, *63*, 456–464.
- Bard, J. A.; Zgombick, J.; Adham, N.; Vaysse, P.; Branchek, T. A.; Weinshank, R. L. Cloning of a Novel Human Serotonin Receptor (5-HT₇) Positively Coupled to Adenylate Cyclase. *J. Biol. Chem.* **1993**, *268*, 23422–23426.
- To, Z. P.; Bonhaus, D. W.; Eglen, R. M.; Jakeman, L. B. Characterisation and Distribution of Putative 5-HT₇ Receptors in Guinea Pig Brain. *Br. J. Pharmacol.* **1995**, *115*, 107–116.
- Branchek, T. A.; Gustafson, E. L.; Durkin, M. M.; Bard, J. A.; Weinshank, R. L. Autoradiographic Localisation of 5-HT₇ Receptor and its mRNA in Rat CNS by Radioligand Binding and In Situ Hybridisation. *Br. J. Pharmacol.* **1994**, *112*, 100F.
- Gustafson, E. L.; Durkin, M. M.; Bard, J. A.; Zgombick, J.; Branchek, T. A. A Receptor Autoradiographic and In Situ Hybridisation Analysis of the Distribution of the 5-HT₇ Receptor in Rat Brain. *Br. J. Pharmacol.* **1996**, *117*, 657–666.
- Schwartz, W. J. A Clinician's Primer on the Circadian Clock: Its Localization, Function and Resetting. *Adv. Int. Med.* **1993**, *38*, 81–106.

- (13) Kikuchi, C.; Nagaso, H.; Hiranuma, T.; Koyama, M. Tetrahydrobenzindoles: Selective Antagonists of the 5-HT₇ Receptor. *J. Med. Chem.* **1999**, *42*, 533–535.
- (14) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An Integrated Software System for Modelling Organic and Bioorganic Molecules using Molecular Mechanics. *J. Comput. Chem.* **1990**, *11*, 440.
- (15) Baldwin, J. M.; Schertler, G. F. X.; Unger, V. M. An Alpha-carbon Template for the Transmembrane Helices in the Rhodopsin Family of G-Protein-coupled Receptors. *J. Mol. Biol.* **1997**, *272*, 144–164.
- (16) Knight, D. W.; Morley, C.; Share, A. C. Complementary Enantioselective approaches to quinolizidine alkaloids. *J. Chem. Soc., Perkin Trans. I* **1994**, 2904.
- (17) Thomas, D. R.; Gittins, S. A.; Collin, L. L.; Middlemiss, D. N.; Riley, G. J.; Hagan, J. J.; Gloger, I.; Ellis, C. E.; Forbes, I. T.; Brown, A. M. Functional characterisation of the human cloned 5-HT₇ receptor (long form); antagonist profile of SB-258719. *Br. J. Pharmacol.* **1998**, *124*, 1300–1306.

JM991151J